Alpha Tau Medical (NASDAQ:DRTS) Trading Up 1.4%

Alpha Tau Medical Ltd. (NASDAQ:DRTS) shares were up 1.4% during trading on Friday . The stock traded as high as $2.13 and last traded at $2.11. Approximately 14,156 shares were traded during trading, a decline of 60% from the average daily volume of 35,198 shares. The stock had previously closed at $2.08.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Alpha Tau Medical in a research note on Wednesday, June 26th.

Alpha Tau Medical Price Performance

The company has a debt-to-equity ratio of 0.07, a quick ratio of 11.60 and a current ratio of 11.60. The company has a 50-day simple moving average of $2.27 and a 200-day simple moving average of $2.67. The company has a market cap of $147.00 million, a price-to-earnings ratio of -5.15 and a beta of 0.75.

Alpha Tau Medical (NASDAQ:DRTS) last released its earnings results on Monday, May 20th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.02. As a group, research analysts predict that Alpha Tau Medical Ltd. will post -0.5 earnings per share for the current year.

Hedge Funds Weigh In On Alpha Tau Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. USAdvisors Wealth Management LLC acquired a new stake in shares of Alpha Tau Medical in the 1st quarter worth approximately $30,000. Aptus Capital Advisors LLC grew its holdings in shares of Alpha Tau Medical by 83.7% in the 2nd quarter. Aptus Capital Advisors LLC now owns 21,945 shares of the company’s stock worth $56,000 after acquiring an additional 10,000 shares during the period. Financial Guidance Group Inc. grew its holdings in shares of Alpha Tau Medical by 83.7% in the 2nd quarter. Financial Guidance Group Inc. now owns 21,945 shares of the company’s stock worth $56,000 after acquiring an additional 10,000 shares during the period. Telemus Capital LLC acquired a new stake in shares of Alpha Tau Medical in the 4th quarter worth approximately $89,000. Finally, Private Advisor Group LLC acquired a new stake in shares of Alpha Tau Medical in the 4th quarter worth approximately $176,000. Institutional investors and hedge funds own 2.65% of the company’s stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.